-
Mashup Score: 1
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Challenges in the treatment of young people with type 2 diabetes - 1 year(s) ago
The increasing prevalence of obesity in children and adolescents has been followed by an increased rate of type 2 diabetes.1 In children and adolescents, type 2 diabetes takes a more aggressive course than in adults with a more rapid decline in β-cell function, high treatment failure, and accelerated development of diabetes-related complications.2 Pharmacological treatments approved by the…
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 3
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Challenges in the treatment of young people with type 2 diabetes - 1 year(s) ago
The increasing prevalence of obesity in children and adolescents has been followed by an increased rate of type 2 diabetes.1 In children and adolescents, type 2 diabetes takes a more aggressive course than in adults with a more rapid decline in β-cell function, high treatment failure, and accelerated development of diabetes-related complications.2 Pharmacological treatments approved by the…
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 4
In this blog post, we will explore the people factor in the future of healthcare. We will examine the role of doctors, nurses, and other professionals
Source: Digital SalutemCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Challenges in the treatment of young people with type 2 diabetes - 1 year(s) ago
The increasing prevalence of obesity in children and adolescents has been followed by an increased rate of type 2 diabetes.1 In children and adolescents, type 2 diabetes takes a more aggressive course than in adults with a more rapid decline in β-cell function, high treatment failure, and accelerated development of diabetes-related complications.2 Pharmacological treatments approved by the…
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Challenges in the treatment of young people with type 2 diabetes - 1 year(s) ago
The increasing prevalence of obesity in children and adolescents has been followed by an increased rate of type 2 diabetes.1 In children and adolescents, type 2 diabetes takes a more aggressive course than in adults with a more rapid decline in β-cell function, high treatment failure, and accelerated development of diabetes-related complications.2 Pharmacological treatments approved by the…
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
Efficacy and safety of the #SGLT2 inhibitor #empagliflozin versus placebo and the #DPP-4 inhibitor #linagliptin versus placebo in #young #people with type 2 #diabetes (#DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO0EJm #T2D